Your session is about to expire
← Back to Search
enVista Aspire intraocular lens (IOL) for Cataract
N/A
Recruiting
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 90 to day 180 after second eye implantation
Awards & highlights
Summary
A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing Cataract Extraction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 90 to day 180 after second eye implantation
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 90 to day 180 after second eye implantation
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean binocular BCDVA (logMAR) at Visit 1
Trial Design
1Treatment groups
Experimental Treatment
Group I: enVista Aspire intraocular lens (IOL)Experimental Treatment1 Intervention
Subjects bilaterally implanted with enVista Aspire EA IOLs.
Find a Location
Who is running the clinical trial?
Bausch & Lomb IncorporatedLead Sponsor
255 Previous Clinical Trials
57,540 Total Patients Enrolled
48 Trials studying Cataract
15,983 Patients Enrolled for Cataract
Share this study with friends
Copy Link
Messenger